Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Integrative Cancer Therapies|November 10, 2010
Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathwayYing-Ming Tsai, Chih-Jen Yang, Ya-Ling Hsu, et al.
Cancers|December 24, 2021
miR-150-5p-Containing Extracellular Vesicles Are a New Immunoregulator That Favor the Progression of Lung Cancer in Hypoxic Microenvironments by Altering the Phenotype of NK CellsWei-An Chang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Biology|September 14, 2022
Characterization of the Oncogenic Potential of Eukaryotic Initiation Factor 4A1 in Lung Adenocarcinoma via Cell Cycle Regulation and Immune Microenvironment ReprogrammingKuan-Li Wu, Yung-Chi Huang, Yu-Yuan Wu, et al.
Oncotarget|December 30, 2017
Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysisYa-Ling Hsu, Jen-Yu Hung, Yen-Lung Lee, et al.
International Journal of Molecular Sciences|January 8, 2023
Ladinin 1 Shortens Survival via Promoting Proliferation and Enhancing Invasiveness in Lung AdenocarcinomaChao-Yuan Chang, Yung-Chi Huang, Hung-Hsing Chiang, et al.
Antibiotics (Basel, Switzerland)|September 5, 2019
Female Asthmatic Patients Have Higher Risk to Develop Gemifloxacin-Associated Skin Rash, Highlighting Unique Delayed Onset CharacteristicsChiou-Mei Wu, Po-Ju Wei, Yu-Ting Shen, et al.
Oncotarget|April 7, 2016
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axisYa-Ling Hsu, Jen-Yu Hung, Shin-Yi Chiang, et al.
Oncotargets and Therapy|April 7, 2016
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatmentChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology|December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Cancers|November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase InhibitorsMing-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Pageof 7